Loading
Latest filing published 04 Mar 2025 for Cara Therapeutics, Inc., €2,664.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Christopher Posner is a declared insider of Tvardi Therapeutics, Inc. (chief executive), with filings sourced from SEC (Form 4). Between 4 June 2019 and 28 February 2025, the trades on record add up to 24 filings.
The open-market record consists of 17 sales worth €396k, with no purchase. Besides market trades, the filings include 7 share grants. 2025 to date brings no purchases and 2 sales.
The record was last updated on 4 March 2025 with an open-market sale (€2,664) in Tvardi Therapeutics, Inc. Typically, a trade is published a median of 4 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
18 of 18 declarations